Shots:

• The first patient has been dosed in the clinical trials to evaluate JAB-21822 (KRAS G12C inhibitor) + Cetuximab in patients with KRAS G12C-mutated advanced colorectal cancer at Peking University Cancer Hospital
• Patients treated with JAB-21822 are insensitive to CT and targeted therapies along with rapid disease progression, short survival, and high unmet clinical needs
• JAB-21822's clinical trials are ongoing as monothx. and in combination therapies in China and the US including monothx. for STK11 co-mutated NSCLC; combination therapy with JAB-3312 (SHP2 inhibitor) to improve KRAS resistance, and in combination with PD-1 mAb to improve the PD-1 response rate

 Ref: PR Newswire | Image: Jacobio